90 related articles for article (PubMed ID: 26948073)
1. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
Makino Y; Watanabe M; Makihara RA; Nokihara H; Yamamoto N; Ohe Y; Sugiyama E; Sato H; Hayashi Y
Asia Pac J Clin Oncol; 2016 Sep; 12(3):259-64. PubMed ID: 26948073
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
3. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
Maeda Y; Hamada A; Sanematsu E; Sasaki JI; Yokoo K; Hira A; Saito H
Cancer Chemother Pharmacol; 2010 Apr; 65(5):953-9. PubMed ID: 19697031
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kasai D; Miyazaki M; Maeno K; Sato S
Cancer Chemother Pharmacol; 2011 Sep; 68(3):669-76. PubMed ID: 21128075
[TBL] [Abstract][Full Text] [Related]
12. Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
Tokunaga S; Nagano T; Kobayashi K; Katsurada M; Nakata K; Yamamoto M; Tachihara M; Kamiryo H; Yokozaki H; Nishimura Y
Anticancer Res; 2017 May; 37(5):2225-2231. PubMed ID: 28476786
[TBL] [Abstract][Full Text] [Related]
13. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
14. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
15. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
Hamada A
Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
[TBL] [Abstract][Full Text] [Related]
16. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
[TBL] [Abstract][Full Text] [Related]
19. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin.
Nagata M; Kimura T; Suzumura T; Kira Y; Nakai T; Umekawa K; Tanaka H; Matsuura K; Mitsuoka S; Yoshimura N; Oka T; Kudoh S; Hirata K
Clin Med Insights Oncol; 2013; 7():31-9. PubMed ID: 23467445
[TBL] [Abstract][Full Text] [Related]
20. Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: application to a clinical pharmacokinetic study.
Ando R; Makino Y; Tamura T; Yamamoto N; Nishigaki R; Kimura T; Yokote N; Yamamoto H
Biomed Chromatogr; 2010 Mar; 24(3):301-6. PubMed ID: 19634123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
